Navigation Links
DATATRAK International, Inc. Receives Notice from NASDAQ
Date:12/8/2008

CLEVELAND, Dec. 8 /PRNewswire-FirstCall/ -- DATATRAK International, Inc. (Nasdaq: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced that it received a notice from the Listing Qualifications Staff (the "Staff") of The NASDAQ Stock Market ("NASDAQ"), dated December 2, 2008, indicating that the Company had not demonstrated compliance with the minimum $2.5 million stockholders' equity requirement for continued listing set forth in NASDAQ Marketplace Rule 4310(c)(3) (the "Rule"). As a result, the Company's securities are subject to delisting from The NASDAQ Capital Market. This notice follows the Company's previous announcement on August 22, 2008 that it had received notification from the Staff stating that the Company did not comply with the Rule and requesting that the Company, in accordance with NASDAQ rules, provide a plan to regain compliance.

The Company intends to request a hearing before a NASDAQ Listing Qualifications Panel (the "Panel") to present its plan to regain compliance. The hearing request will stay the delisting of the Company's common shares pending the Panel's decision following the hearing. There can be no assurance that the Panel will grant the Company's request for continued listing on The NASDAQ Capital Market.

About DATATRAK International, Inc.

DATATRAK International, Inc. is a worldwide technology company focused on the provision of multi-component eClinical solutions and related services for the clinical trials industry. The Company delivers a complete portfolio of software products that were created in order to accelerate clinical research data from investigative sites to clinical trial sponsors and ultimately the FDA, faster and more efficiently than manual methods or loosely integrated technologies. DATATRAK's eClinical software suite can be deployed worldwide through an ASP offering or in a licensed Enterprise Transfer model that fully empowers its clients. The DATATRAK software suite and its earlier versions have successfully supported hundreds of international clinical trials involving thousands of clinical research sites and encompassing tens of thousands of patients in 59 countries. DATATRAK International, Inc.'s product suite has been utilized in some aspect of the clinical development of 16 drugs and one medical device that have received regulatory approval from either the United States Food and Drug Administration or counterpart European bodies. DATATRAK International, Inc. has offices located in Cleveland, Ohio, and Bryan, Texas. Its common stock is listed on the NASDAQ stock Market under the ticker symbol "DATA". Visit the DATATRAK International, Inc. web site at www.datatrak.net.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward- looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors (including those specified below) which are difficult to predict and, in many instances, are beyond the control of the Company. Factors that may cause actual results to differ materially from those in the forward-looking statements include the limited operating history on which the Company's performance can be evaluated; the ability of the Company to continue to enhance its software products to meet customer and market needs; fluctuations in the Company's quarterly results; the viability of the Company's business strategy and its early stage of development; the timing of clinical trial sponsor decisions to conduct new clinical trials or cancel or delay ongoing trials; the Company's dependence on major customers; government regulation associated with clinical trials and the approval of new drugs; the ability of the Company to compete in the emerging EDC market; losses that potentially could be incurred from breaches of contracts or loss of customer data; the inability to protect intellectual property rights or the infringement upon other's intellectual property rights; the Company's success in integrating its acquisition's operations into its own operations and the costs associated with maintaining and/or developing two product suites; delisting of the Company's common shares from the Nasdaq Capital Market; and general economic conditions such as the rate of employment, inflation, interest rates and the condition of capital markets. This list of factors is not all-inclusive. In addition, the Company's success depends on the outcome of various strategic initiatives it has undertaken, all of which are based on assumptions made by the Company concerning trends in the clinical research market and the health care industry. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE DATATRAK International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. DATATRAK International Management To Host Conference Call on November 8, 2007 To Discuss Third Quarter and Nine Month Operating Results for 2007
2. DATATRAK International, Inc. Announces 2007 Third Quarter and Nine Month Operating Results
3. DATATRAK International Launches Innovative, Interactive Educational Webcast Series
4. DATATRAK to Present at the Roth Capital Partners 20th Annual Orange County Stock Conference
5. DATATRAK Closes Second Multi-Year Enterprise Agreement with European Clinical Trial Sponsor
6. DATATRAK International Management to Host Conference Call on February 26, 2008 to Discuss Fourth Quarter and Full Year Operating Results for 2007
7. DATATRAK International Reports Fourth Quarter and Full Year Results for 2007
8. DATATRAK Announces Restructured Senior Management Team
9. Ease-of-Use and Intuitive Nature of the DATATRAK eClinical(TM) Platform Allows for Further Operational Efficiencies
10. DATATRAK International, Inc. Receives Notice From Nasdaq
11. DATATRAK International Management to Host Conference Call on November 6, 2008 to Discuss Third Quarter and Nine Month Operating Results for 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... ... the largest manufacturer of oats in China, is now aiming at global business expansion, ... globally as one of the healthiest cereals, XieQingkui, the founder of Seamild, strongly recommends ... sow the seed of good karma. Buddhism spirit featuring benevolence and sacrifice are the ...
(Date:1/21/2017)... ... 21, 2017 , ... Pacifica Graduate Institute’s Alumni Association announced ... events for its annual meeting “Coming Home 2017,” an activity-packed weekend of educational ... will be held on Friday January 27 through Sunday, January 29, 2017 at ...
(Date:1/21/2017)... ... 21, 2017 , ... Santa Rosa Orthopaedics (SRO) is excited ... 167 Lynch Creek Way. The Petaluma office features three comfortable patient exam rooms, ... services and on-site x-ray services. Two multi-specialist orthopaedic surgeons Dr. Neema Pourtaheri ...
(Date:1/21/2017)... ... 21, 2017 , ... The Nobel Biocare™ dental implant company ... for its creos™ line of bone regenerative products. Specifically, the Nobel ... utilizes creos™ allo.gain™ bone graft for a variety of bone reconstruction procedures. In ...
(Date:1/20/2017)... ... 2017 , ... A new partnership between Goodwill® and Roadie, Inc. aims to ... from clothes to couches to dressers and bicycles. Roadie — the national on-the-way delivery ... Goodwill donation center through February 28th. , “January is an exciting time when ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... 2017 ARMO BioSciences, Inc., a late-stage immuno-oncology ... Company,s lead investigational immuno-oncology drug AM0010 (PEGylated Interleukin-10) at ... Society of Clinical Oncology (ASCO), taking place January 19-21, ... "AM0010 induces the expansion of novel ... cells in the blood and tumors of our patients," ...
(Date:1/20/2017)... Jan 20, 2017 Research and Markets ... Market (by Devices, Implant Types, OTC Amplifiers, Diagnostic Instruments), Sales ... their offering. ... Global Hearing Aids Market Sales Volume, Company Analysis and ... high-growth hearing aid industry. The growing prevalence of ...
(Date:1/20/2017)... PARK, Fla. , Jan. 20, 2017 Wells ... located at 3796 Howell Branch Rd in Winter ... Winter Park . Operations have been consolidated ... Specialty Pharmacy is also pleased to announce that Chad ... to President of the Company effective immediately. Mr. Tomlinson is ...
Breaking Medicine Technology: